Results 241 to 250 of about 452,772 (333)
Rapid Microfluidic Drug Sensitivity Testing Within 5 Days Using Minimal Clinical Tumor Samples
This study develops the air‐punched fabrication approach for nanoliter‐scale microcavity arrays with ultra‐smooth microcavity surfaces, with which rapid formation and 3D culture of tumor cell spheroids from small numbers of cell samples, as well as high‐throughput drug sensitivity testing can be achieved within 5 days.
Yi‐Xue Chen +11 more
wiley +1 more source
Ventricular-Arterial Coupling in Heart Failure with Preserved Ejection Fraction: A Bibliometric Review and Clinical Implications. [PDF]
Li T, Luo Y, Zhao L, Lu F, Zhang B.
europepmc +1 more source
This study successfully engineered vascularized liver organoids (3HLOs) by co‐culturing human reprogrammed hepatocyte‐like cells (hrHLs) with human umbilical vein endothelial cells (HUVECs) and human umbilical mesenchymal stem cells (HUMSCs). Upon implantation, the 3HLOs established functional vascular anastomosis with the host circulation and ...
Kangdi Yang +13 more
wiley +1 more source
Early pathological changes of coronary microvasculation in heart failure with preserved ejection fraction. [PDF]
Guo Z +5 more
europepmc +1 more source
Intravenous iron therapy in heart failure with preserved ejection fraction: how far have we walked? [PDF]
Veraprapas Kittipibul, Robert J. Mentz
openalex +1 more source
Mature red blood cells (RBCs) can capture extracellular DNA, with short fragments homologous to cfDNA. This uptake is mediated by apoptotic bodies, which induce RBC oxidative stress, deformation, and accelerated in vivo clearance. The rbcDNA abundance correlates with tumor burden and therapeutic response, highlighting its potential as a liquid biopsy ...
Zihang Zeng +20 more
wiley +1 more source
Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment. [PDF]
Peikert A +3 more
europepmc +1 more source
By integrating a convergent molecular platform strategy, this study designed a novel dual‐target C5 to combat multidrug‐resistant Gram‐negative bacteria. C5 synergistically enhances antibiotic efficacy by inhibiting efflux pumps and increasing bacterial membrane permeability.
Jiale Dong +11 more
wiley +1 more source

